Applied Materials Inc AMAT Valuation Assessment Following a 177 12Month Share Price Surge NPCE Neuropace posts far narrower than expected Q4 2025 loss even as shares dip slightly today NRXP NRX Pharmaceuticals shares climb 352 percent as investors shrug off worse than expected Q4 2025 EPS miss